secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001600620-24-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia reports 2023 net product revenue up 53% to $158.5M; ends strategic review, initiates $150M buyback
--------------------------------------------------------------------------------

- Net product revenue $158.5M (+53% YoY); net loss $78.0M ($0.54/shr) vs $108.2M loss in 2022.
- Discontinues AUR200/AUR300 development; expects $11-15M Q1'24 charge and $50-55M annual savings; headcount cut ≥25% (non-commercial).
- Board authorizes up to $150M share repurchase; max subject to Canadian regulatory approval; purchases start Feb 21, 2024.
- Strategic review concluded after engaging 60+ parties; one non-binding expression of interest did not lead to formal offer.
- Reaffirms 2024 net product revenue guidance of $200-220M; 2,066 patients on LUPKYNIS at year-end (vs 1,525).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/0001600620-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/auph-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001600620-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer